首頁 > 市場調查報告書 > 醫療設備

體外診斷

市場調查報告書

商品編碼

1620334

全球凝血分析儀市場規模：地區、範圍和預測

Global Blood Coagulation Analyzer Market Size By Technology (Optical Technology, Electrochemical Technology), By Test Type (APTT, Fibrinogen, PT), By Distribution Channels (Clinical Laboratory, Point-of-Care (POC)), By Geographic Scope And Forecast

出版日期: 2024年11月01日 | 出版商:

Verified Market Research | 英文 202 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

凝血分析儀市場規模及預測

2024年凝血分析儀市場規模預計為40.7億美元，預計2024年至2031年複合年增長率為5.90%，到2031年預計將達到64.3億美元。凝血分析儀是一種評估血液凝固能力的特殊醫療設備，對於識別和治療涉及異常出血或凝血的疾病至關重要。其他活動評估各種凝血參數，例如凝血酶原時間 (PT)、活化部分凝血活酶時間 (aPTT) 和纖維蛋白原水平。這項發現將有助於醫療保健提供者監測服用抗凝血劑的患者、診斷血友病等凝血障礙以及管理深部靜脈栓塞和肺栓塞等疾病。透過提供準確和及時的數據，這些技術有助於確保有效和安全的患者護理。

由於技術的改進和個人化治療需求的增加，凝血分析儀前景光明。現場護理測試、與電子健康記錄的整合以及家庭使用的小型化預計將提高凝血測試的簡單性和準確性。

此外，開發能夠進行詳細檢查和即時監測的更複雜的分析儀將改善患者的治療結果並簡化臨床操作。隨著醫療保健產業的發展，這些分析儀對於凝血障礙的治療和精準醫學的進步將變得至關重要。

世界凝血分析儀市場動態

塑造全球凝血分析儀市場的關鍵市場動態

主要市場驅動因子

血液疾病盛行率增加：

血液疾病盛行率不斷上升：由於患者血液疾病盛行率不斷上升，對凝血分析儀的需求量很大。根據世界血友病聯合會2019年度全球調查顯示，全球血友病患者超過32.4萬人，比前一年增加7%。

老年人口成長：

隨著世界人口老化，心血管疾病和凝血障礙的風險增加，增加了對凝血測試的需求。根據聯合國《2019年世界人口展望》報告，到2050年，全球六分之一的人將超過65歲，而2019年這一比例為十分之一。

外科手術的增加：

隨著全球外科手術的增加，需要在術前和術後護理中進行更多的凝血測試。根據《柳葉刀》2021 年發表的報告，2008 年至 2018 年間，全球進行的外科手術數量增加了 38.2%，每年達到 3.13 億例。

凝血分析儀的技術進步：

凝血分析儀的技術進步，例如更高的準確性和更快的結果，正在推動市場擴張。根據美國國立衛生研究院 (NIH) 2022 年的報告，典型的實驗室程序需要 30 到 60 分鐘，而護理點凝血測試設備現在只需大約 1 到 3 分鐘即可得出結果。

主要問題

技術複雜性：

凝血分析儀是複雜的設備，需要先進的技術和精密的工程。在保持準確性和可靠性的同時跟上技術的快速進步可能很困難。為了保持競爭力，製造商必須不斷創新和升級其系統，這需要大量的研發成本。

資料管理：

現代凝血分析儀會產生大量數據，必須仔細記錄、儲存和處理這些數據。有效的數據管理系統對於確保結果可靠且易於存取至關重要。將這些技術與其他醫院資訊系統整合可能很困難。

產品校準與維護：

需要定期校準和維護，以確保凝血分析儀的準確性和可靠性。對於資源有限的醫療機構來說，這種持續的需求尤其具有課題性，並且可能會影響營運效率和採用這些設備的成本。

成本高：

凝血分析儀的購買和維護費用昂貴。這包括設備、消耗品以及定期校準和維護需求。對於小型診所和實驗室來說，如此高的價格令人望而卻步，並限制了先進凝血診斷的取得。

主要趨勢

即時偵測

凝血的即時 (POC) 測試變得越來越受歡迎，因為它們可以在現場快速提供結果，而不是將樣本送到中心實驗室。這一趨勢是由對更快的診斷結果和提高患者便利性的渴望所推動的。 POC 設備變得越來越小且更易於使用，從而能夠在各種臨床環境（包括急診和門診）中更快地做出決策。

與電子健康記錄 (EHR) 整合：

凝血分析儀越來越多地與電子健康記錄 (EHR) 集成，以加快數據管理並改善患者護理。該介面提供流暢的數據傳輸、即時存取患者資訊以及改善醫療保健提供者之間的協作，從而提高凝血測試和管理的整體效率。

緊湊性與便攜性：

小型化、攜帶式凝血分析儀的發展是一大趨勢。這些小型設備用途廣泛且方便，可以在各種環境下進行凝血測試，包括偏遠地區和家庭護理。便攜式分析儀滿足了對分散式測試解決方案不斷增長的需求。

先進技術與自動化：

由於自動化和技術的進步，凝血分析儀變得越來越有用。自動化樣品處理、數據處理和結果報告等功能變得越來越普遍，提高了準確性、消除了人為錯誤並提高了測試吞吐量。

Blood Coagulation Analyzer Market size was valued at USD 4.07 Billion in 2024 and is projected to reach USD 6.43 Billion by 2031 , growing at a CAGR of 5.90% from 2024 to 2031. A blood coagulation analyzer is a specialized medical instrument that evaluates the blood's ability to clot, which is critical in identifying and treating disorders involving irregular bleeding or clotting. These analyzers assess a variety of coagulation parameters, including prothrombin time (PT), activated partial thromboplastin time (aPTT), and fibrinogen levels, among others. The findings assist healthcare providers in monitoring patients undergoing anticoagulant medication, diagnosing clotting diseases such as hemophilia, and managing illnesses such as deep vein thrombosis and pulmonary emboli. By providing precise and timely data, these technologies help to ensure effective and safe patient care.

The blood coagulation analyzers look positive, thanks to technological improvements and rising demand for individualized therapy. Point-of-care testing, integration with electronic health records, and home miniaturization are all predicted to improve the ease and accuracy of coagulation tests.

Furthermore, the development of more complex analyzers capable of thorough testing and real-time monitoring is likely to enhance patient outcomes and streamline clinical operations. As the healthcare industry evolves, these analyzers will be critical to the treatment of coagulation diseases and the growth of precision medicine.

Global Blood Coagulation Analyzer Market Dynamics

The key market dynamics that are shaping the global blood coagulation analyzer market include:

Key Market Drivers:

Increasing Prevalence of Blood Disorders:

Blood coagulation analyzers are in high demand due to the increasing prevalence of blood diseases among patients. According to the World Federation of Hemophilia's Annual Global Survey 2019, there were over 324,000 people with hemophilia globally, up 7% over the previous year.

Rising Geriatric Population:

As the world's population ages, there is a greater risk of cardiovascular disease and clotting disorders, increasing the demand for coagulation tests. According to the United Nations' World Population Prospects 2019 report, by 2050, one in every six persons worldwide will be over the age of 65, up from one in every eleven in 2019.

Increasing Surgical Procedures:

Increasing surgical procedures worldwide need more coagulation tests for pre- and post-operative care. According to a report published in The Lancet in 2021, the number of surgical procedures performed worldwide increased by 38.2% between 2008 and 2018, reaching 313 million each year.

Technological Advancements in Coagulation Analyzers:

Technological advances in blood coagulation analyzers, including increased accuracy and faster results, are driving market expansion. According to a 2022 National Institutes of Health (NIH) report, point-of-care coagulation testing equipment can already offer results in as little as 1-3 minutes, compared to typical laboratory procedures that take 30-60 minutes.

Key Challenges:

Technological Complexity:

Blood coagulation analyzers are complex instruments that require advanced technology and precision engineering. It might be difficult to keep up with rapid technological advances while maintaining accuracy and reliability. To remain competitive, manufacturers must consistently innovate and upgrade their systems, which requires major expenditure in R&D.

Data Management:

Modern coagulation analyzers generate a huge amount of data, which must be carefully recorded, stored, and processed. Effective data management systems are essential for ensuring that results are dependable and easily accessible. Integrating these technologies with other hospital information systems can be difficult.

Product Calibration and Maintenance:

Regular calibration and maintenance are required to ensure the accuracy and reliability of coagulation analyzers. This continual necessity can be difficult, particularly for healthcare facilities with limited resources, and may impact the operational efficiency and cost of employing these devices.

High Costs:

Blood coagulation analyzers can be expensive both to purchase and to maintain. This includes the cost of the equipment, consumables, and the necessity for periodic calibration and servicing. These high prices can be prohibitive for smaller clinics and laboratories, restricting access to advanced coagulation diagnostics.

Key Trends:

Point-of-Care Testing:

Point-of-care (POC) testing for blood coagulation is becoming more popular, as it provides quick, on-site results rather than sending samples to a central lab. This trend is motivated by the desire for faster diagnostic results and more patient convenience. POC devices are becoming smaller and more user-friendly, allowing for rapid decision-making in a variety of clinical settings, including emergency rooms and outpatient clinics.

Integration with Electronic Health Records (EHRs):

Blood coagulation analyzers are increasingly being linked to electronic health records (EHRs) to expedite data administration and improve patient care. This interface offers smooth data transfer, real-time access to patient information, and improved coordination among healthcare providers, hence increasing the overall efficiency of coagulation testing and management.

Miniaturization and Portability:

The development of small and portable blood coagulation analyzers is a major trend. These small instruments provide versatility and simplicity, enabling coagulation testing in a variety of contexts, including remote locations and home care settings. Portable analyzers address the growing demand for dispersed testing solutions.

Advanced Technology and Automation:

Blood coagulation analyzers are becoming more useful as a result of advances in automation and technology. Features such as automated sample handling, data processing, and result reporting are becoming increasingly common, enhancing accuracy, eliminating manual errors, and increasing test throughput.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

Global Blood Coagulation Analyzer Market Regional Analysis

Here is a more detailed regional analysis of the global blood coagulation analyzer market:

North America:

North America continues to lead the blood coagulation analyzer market due to its excellent healthcare infrastructure, cutting-edge medical research, and the high prevalence of chronic disorders that necessitate regular coagulation monitoring. The region's well-established healthcare system promotes the widespread use of sophisticated diagnostic instruments, such as blood coagulation analyzers. According to the CDC, almost 900,000 Americans suffer from deep vein thrombosis or pulmonary embolism each year, with up to 100,000 deaths attributed to these illnesses. This high incidence highlights the urgent necessity for precise and rapid coagulation testing. The American Heart Association's 2024 update states that cardiovascular disorders affect roughly half of American adults, with many requiring continuing anticoagulant medication, increasing the requirement for dependable coagulation monitoring.

North America's enormous investments in medical technology and research strengthen its market supremacy. According to the National Institutes of Health, the region will account for more than 40% of worldwide healthcare R&D spending in 2023, with a large share going toward diagnostic technology such as blood coagulation analyzers. A growing emphasis on preventive healthcare and early detection is also a crucial driver, as indicated by a 2024 study that predicts an 8.5% annual growth rate in point-of-care coagulation testing across North America. This emphasis on rapid and accessible diagnostic solutions continues to drive market growth, establishing North America's dominant position in the blood coagulation analyzer sector.

Asia Pacific:

The Asia-Pacific area is rapidly emerging as the fastest-growing market for blood coagulation analyzers, owing to several revolutionary forces that are transforming the healthcare environment. Cardiovascular disorders account for 31% of all deaths in the region and about 6.2 million deaths per year, the extreme need for enhanced coagulation monitoring. This high prevalence contributes significantly to the rising demand for blood coagulation analyzers. The region's aging population is driving market growth. The United Nations Economic and Social Commission for Asia and the Pacific predicts that the number of older people in the region will quadruple by 2050, increasing the prevalence of age-related coagulation diseases and driving up the need for monitoring systems.

Rising healthcare expenditure in Asia-Pacific is also driving market expansion. This increased investment promotes the expansion of healthcare infrastructure and the availability of advanced diagnostic technology. Improved access to healthcare services for the region's growing middle class, combined with technology developments and improved awareness of blood problems, is fueling market growth. According to reports, point-of-care coagulation testing equipment use in India is growing at a 12% yearly rate, suggesting a regional trend toward rapid and accessible diagnostic options.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

Global Blood Coagulation Analyzer Market: Segmentation Analysis

The Global Blood Coagulation Analyzer Market is Segmented on the basis of Technology, Test Type, Distribution Channel, And Geography.

Blood Coagulation Analyzer Market, By Technology

Optical Technology
Mechanical Technology
Electrochemical Technology

Based on Technology, the market is bifurcated into Optical Technology, Mechanical Technology, and Electrochemical Technology. Optical technology leads the blood coagulation analyzer market due to its great sensitivity, accuracy, and convenience. This method uses light to measure coagulation parameters, providing accurate and consistent results. On the other hand, electrochemical technology is emerging as the fastest-growing segment, given to its potential for downsizing and point-of-care applications. This method uses electrical signals to measure coagulation parameters, allowing for portable and convenient quick testing in a variety of scenarios.

Blood Coagulation Analyzer Market, By Test Type

APTT
D-Dimer
Fibrinogen
PT

Based on Test Type, the market is segmented into APTT, D-Dimer, Fibrinogen, and PT. The blood coagulation analyzer market is divided into two dominating segments: APTT and PT. APTT assesses the internal process of coagulation, whereas PT evaluates the extrinsic pathway. These tests are commonly used to assess patients with bleeding or clotting issues. D-dimer is a new segment that is quickly gaining popularity due to its significance in identifying deep vein thrombosis (DVT) and pulmonary embolism (PE). The rising prevalence of these disorders, combined with the development of more sensitive D-dimer testing, has accelerated its expansion.

Blood Coagulation Analyzer Market, By Distribution Channel

Clinical Laboratory
Point-of-Care (POC)
Hospitals

Based on Distribution Channel, the market is segmented into Clinical Laboratory, Point-of-Care (POC), and Hospitals. Hospitals dominate the blood coagulation analyzer market due to requiring extensive testing for a diverse spectrum of patients. However, point-of-care (POC) testing is emerging as the most rapidly rising area. POC devices provide fast outcomes at the bedside, allowing for timely decision-making in critical care settings. The growing demand for decentralized testing, combined with technological developments in POC analyzers, is propelling their implementation in a variety of healthcare settings.

Blood Coagulation Analyzer Market, By Geography

North America
Europe
Asia Pacific
Rest of the World
On the basis of Geography, the Global Blood Coagulation Analyzer Market is classified into North America, Europe, Asia Pacific, and the Rest of the World. North America continues to dominate the blood coagulation analyzer market due to its established healthcare infrastructure, advanced medical research, and high prevalence of chronic disorders. However, Asia-Pacific is emerging as the fastest-growing area, owing to reasons such as rising healthcare spending, increased awareness of blood coagulation disorders, and the expansion of healthcare infrastructure.

Key Players

The "Global Blood Coagulation Analyzer Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are
Abbott Laboratories, Danaher Corporation, Siemens Healthineers AG, Sysmex Corporation, Thermo Fisher Scientific, Inc., Maccura Biotechnology Co. Ltd., Diagnostica Stago SAS, and Helena Laboratories.
The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Blood Coagulation Analyzer Market Recent Developments
In July 2022, HORIBA Medical will release the latest Yumizen G800 and G1550 hemostasis analyzers, as well as a line of handy ready-to-use reagents for common blood coagulation assays. With the growth of its product line, HORIBA Medical now offers a full array of hemostasis systems and innovative reagents to laboratories of all sizes and needs.
In October 2021, Trivitron Healthcare announced the launch of a new line of Coagulation Analyzer products developed by Diagon Ltd. The newly announced product line includes the COAG Line, which includes automated, semi-automated, and POC systems developed by Diagon Hungary. These cutting-edge technologies are critical in decreasing bleeding risks during extensive procedures, as well as evaluating the efficacy of hemostatic treatments and anticoagulants.
In October 2021, Trivitron Healthcare, a medical device business, unveiled a new line of Coagulation Analyzer products in India, produced by Diagon Ltd.
In February 2021, Siemens Healthineers and Sysmex Corporation announced the renewal of their long-standing global supply, distributorship, sales, and service agreement for a broad portfolio of hemostasis devices, which included a multi-year extension.